Is Cibinqo Approved for Skin Conditions?
Yes, Cibinqo (abrocitinib) is FDA-approved for treating moderate-to-severe atopic dermatitis (eczema) in adults whose skin symptoms aren't controlled by topical treatments or when those treatments aren't advisable.[1] It's a daily oral tablet that targets JAK1 to reduce inflammation and itching.
How Does Cibinqo Work for Eczema?
Cibinqo inhibits Janus kinase 1 (JAK1), a protein involved in the inflammatory pathways driving atopic dermatitis. Clinical trials showed it clears skin in 40-60% of patients (depending on dose) after 12 weeks, with many achieving at least 75% improvement in eczema severity scores.[1][2]
What Skin Conditions Is It Used For?
Primarily atopic dermatitis. It's not approved for psoriasis, acne, or other dermatoses. Off-label use for other skin issues lacks strong evidence and isn't recommended.[1]
Who Makes Cibinqo and When Did It Launch?
Pfizer manufactures and markets Cibinqo. FDA approval for atopic dermatitis came in September 2021, following priority review.[1]
Common Side Effects on Skin and Beyond
Skin-related side effects are uncommon but can include acne or rash (affecting ~3-5% of users). More frequent issues: upper respiratory infections (15-20%), nausea (10%), and headaches (8%). Serious risks include infections, blood clots, and malignancies—requires monitoring.[1][2]
How Does It Compare to Dupixent or Rinvoq for Eczema?
| Drug | Type | Dosing | Skin Clearance Rate (Week 16) | Key Difference |
|------|------|--------|-------------------------------|---------------|
| Cibinqo | Oral JAK inhibitor | 100/200 mg daily | ~40-62% (EASI-75) | Pill convenience; boxed warning for clots/cancer |
| Dupixent | Injectable IL-4/IL-13 blocker | Every 2-4 weeks | ~45-75% (EASI-75) | Fewer systemic risks; pricier injections |
| Rinvoq | Oral JAK inhibitor | 15/30/45/150 mg daily | ~40-70% (EASI-75) | Broader approvals (e.g., rheumatoid arthritis); similar profile[2] |
Cibinqo suits patients avoiding injections but demands lab monitoring.
Cost and Access for Skin Treatment
List price is ~$6,000-$7,000/month without insurance. Patient assistance via Pfizer's program can reduce it. Biosimilars unlikely soon due to patents expiring around 2030-2035 (check DrugPatentWatch.com for updates).3
When Does the Patent Expire?
U.S. patents on abrocitinib extend to at least 2032, with pediatric exclusivity possibly to 2033. No major challenges listed yet.3
[1]: FDA Label - Cibinqo (pfizer.com/products/product-detail/cibinqo)
[2]: NEJM - Abrocitinib vs Placebo/Dupilumab Trials (nejm.org/doi/full/10.1056/NEJMoa2100683)